Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Alcohol Use Disorder (AUD)

Mescaline for Alcohol Use Disorder (AUD)

8 papers and 0 clinical trials exploring mescaline as a treatment for alcohol use disorder (aud).

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationOver 100 million cases worldwide, making AUD the most common substance use disorder.

Alcohol Use Disorder (AUD)

Alcohol Use Disorder (AUD) is a prevalent condition characterised by an inability to control alcohol consumption despite adverse consequences. Emerging research indicates that psychedelics may offer promising therapeutic avenues for treating AUD, with various compounds showing potential in clinical trials.

Full Alcohol Use Disorder (AUD) profile

Academic Research

8 papers
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Paywallmeta

Mescaline: The forgotten psychedelic

This review (2022) explores mescaline's pharmacological and behavioural effects using preclinical and clinical research. The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics i.e. binding at the 5HT2A receptor. Mescaline can improve well-being and mental health conditions, particularly alcohol use disorder.

Published
October 14, 2022
Journal
Neuropharmacology
Authors
Narine, K., Campbell, I., Dyck, J., Nutt, D. J., Vamvakopulou, I. A.
Open Accessmeta

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

This systematic review of 27 human and preclinical studies (2000–2021) finds that classic psychedelics—particularly psilocybin—show promising but inconclusive evidence for reducing alcohol consumption. Human studies are hampered by small samples and methodological limitations and preclinical data are scarce and mixed, so higher-quality trials are needed to establish efficacy and mechanisms.

Published
August 31, 2022
Journal
Addiction Biology
Authors
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V., Bühler, K. M., Giné, E., López-Moreno, J.
Paywallmeta

Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation

This book chapter (2022) reviews the use of psilocybin in the treatment of addiction with a specific focus on smoking (tobacco use disorder, TUD). After exploring the historical use of psychedelics to treat addiction, modern research on the topic is reviewed. The anti-addiction properties of psychedelics differ but are consistent with the notion that the persisting positive behaviour change prompted by psychedelic therapy is due to the amplification of psychotherapeutic processes.

Published
June 16, 2022
Journal
Current Topics in Behavioral Neurosciences
Authors
Johnson, M. W.
Open Accessindividual

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

This survey study (n=452) found that the use of mescaline led to improvements in scores on clinical conditions for those suffering from clinical conditions (anxiety 80%, depression 86%, PTSD & AUD 76%). Those who scored higher on acute mystical experience (MEQ30), ego dissolution, and psychological insight had larger improvement than those who scored lower.

Published
March 23, 2021
Journal
ACS Pharmacology and Translational Science
Authors
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., Davis, A. K.
Open Accessindividual

Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder

This study describes the treatment trajectories of (n=3) participants administered with psilocybin (25-40mg/70kg) in a double-blind placebo-controlled clinical trial investigating the treatment of alcoholism (AUD). These participants experienced acute and lasting alterations in their perceptions of self, in the quality of their baseline consciousness, and in their relationship with alcohol. Increased mindfulness, and control over choices, were also reported following the treatment.

Published
February 20, 2018
Journal
Frontiers in Pharmacology
Authors
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., Mennenga, S. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Alcohol Use Disorder (AUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Alcohol Use Disorder (AUD) trials Full Mescaline profile Full Alcohol Use Disorder (AUD) profile